An observational study in Weakness, Muscle, sponsored by Ahram Canadian University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Ahram Canadian University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Muscle Weakness with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Muscle Weakness · Egypt.
Among the 16 studies in Muscle Weakness with a site in Egypt, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 10th registered.
478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.
Browse Muscle Weakness studies →4 of the 16 studies in Muscle Weakness with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 50–70
Cairo University · Sites in Egypt
Ages 25–45
Cairo University · Sites in Egypt
Ages 27–40
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 66 across 107 observational studies indexed under Muscle Weakness.
Median enrollment 61 across the 9 interventional studies, 58 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.
Ahram Canadian University has 1 study filed under Muscle Weakness — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscle Weakness with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07692126Cairo UniversityCore Stability vs Scapular Stabilization on Hand Grip Strength in Chronic Myofascial Neck Pain | 2027-01-01 |
| NCT07855341Ain Shams UniversityLow-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Muscle Weakness with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will use electromyography and dynamometry to evaluate gluteal muscle activation during the Trendelenburg hip abduction test in different hip positions.
The Trendelenburg test is commonly used to assess hip abductor weakness. However, it is unclear which hip position during this test best isolates gluteal muscle function. This study will measure gluteus medius and minimus activation and hip abduction force in 30 healthy participants performing the Trendelenburg test. Different hip flexion, extension, adduction and abduction angles will be evaluated to determine which position optimally targets the gluteal muscles. Results may enhance utilization of the Trendelenburg test in clinical practice.
Healthy men and women aged 18-45 recruited from the local community.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At least 30 healthy adult participants aged 18-45 years performing the Trendelenburg hip abduction test
Diagnostic Test: Trendelenburg hip abduction test
The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
Gluteus Medius Activation
Mean EMG activity of the gluteus medius during the Trendelenburg test at different hip positions. Measured bilaterally in microvolts (μV).
Time frame: Baseline
Gluteus Minimus Activation during Trendelenburg Test
Mean muscle activation amplitude (measured in microvolts, μV) of the gluteus minimus during the Trendelenburg hip abduction test across a range of hip flexion, extension, adduction and abduction angles from 0 to 45 degrees. Measured bilaterally using surface electromyography electrodes placed on the muscle belly of the gluteus minimus.
Time frame: Baseline
Hip Abduction Strength during Trendelenburg Test
Maximum voluntary isometric hip abduction strength (measured in Newtons, N) during the Trendelenburg hip abduction test maneuver. Measured bilaterally at each combination of hip flexion, extension, adduction and abduction angles using a stabilized handheld dynamometer placed just proximal to the lateral femoral condyle.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2023; primary completion for Dec 2023, 4 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahram Canadian University